Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/eisai-co-ltd" target="_blank" data-smartkarma-citation="entities:21001:1" rel="noopener">Eisai Co Ltd (4523 JP)</a>  is a global R&amp;D based pharmaceutical company who has positioned neurology and oncology as its therapeutic areas of focus. Since October 2017, Biogen and Eisai have collaborated on the development and commercialisation of Aducanumab (BIIB037), an investigational treatment for Alzheimer’s disease. The US FDA accepted the Biologics License Application (BLA) for Aducanumab for review in August 2020 and was granted priority review status.US FDA briefing documents (dated 04th November) states that the FDA staff have enough data to approve the treatment, which would become the first new Alzheimer’s therapy in nearly two decades. The briefing documents have been released ahead of a meeting of outside advisers who will issue a non-binding vote on whether to recommend Aducanumab’s approval. These experts are scheduled to meet on Friday, 06th November.Eisai’s shares have climbed 18% during Thursday’s trading following the release of the FDA briefing document. In this insight, we take a look at Aducanumab, the collaboration agreement between Eisai and Biogen, and the impact on the company’s fundamental and valuation if the drug is approved by the FDA.

Eisai Co Ltd (4523 JP)  is a global R&amp;D based pharmaceutical company who has positioned neurology and oncology as its therapeutic areas of focus. Since October 2017, Biogen and Eisai have collaborated on the development and commercialisation of Aducanumab (BIIB037), an investigational treatment for Alzheimer’s disease. The US FDA accepted the Biologics License Application (BLA) for Aducanumab for review in August 2020 and was granted priority review status.US FDA briefing documents (dated 04th November) states that the FDA staff have enough data to approve the treatment, which would become the first new Alzheimer’s therapy in nearly two decades. The briefing documents have been released ahead of a meeting of outside advisers who will issue a non-binding vote on whether to recommend Aducanumab’s approval. These experts are scheduled to meet on Friday, 06th November.Eisai’s shares have climbed 18% during Thursday’s trading following the release of the FDA briefing document. In this insight, we take a look at Aducanumab, the collaboration agreement between Eisai and Biogen, and the impact on the company’s fundamental and valuation if the drug is approved by the FDA.

에자이: 신약 후보물질 긍정적 검토에 주가 급등, 승인 시 블록버스터급 성장 가능성